The capacity problem in nuclear medicine and why you should care

Demand for nuclear medicine is growing rapidly, driven by new opportunities in theranostics, neurology, and cardiology. Yet many departments struggle to keep pace, facing longer waiting lists, rising tracer costs, and increasing pressure on capacity. This whitepaper explores the cost of inaction and the clinical, operational, and financial benefits available to departments that act now.

The overlooked opportunity: timely diagnostics as a lever for successful healthcare

PET scans are increasingly central to treatment decisions across cancer, yet the time between referral and scan receives almost no attention. The evidence on treatment delays is sobering: a four-week wait can raise mortality by over 10% in some indications, and the gains from faster diagnostics may outweigh those of many costly new therapies. This piece examines why timely PET access matters, what the literature says about delay-related harm, and how expanding scanner capacity fits into a broader case for rethinking clinical infrastructure.

Why AI is the missing piece in amyloid PET imaging for Alzheimer's

Anti-amyloid therapies have made PET central to Alzheimer's care, but neurodegeneration staging is still missing from most workflows. Dual-phase amyloid PET offers a fix, if the noise problem in short acquisitions can be solved. New research shows how deep learning denoising gets there.

More patients, same scanner

Ziekenhuis Oost-Limburg (ZOL) was facing a familiar pressure: one PET scanner, rising referrals, and waiting times stretching past a month. Rather than invest in new equipment, the department turned to NUCLARITY to unlock capacity from the infrastructure it already had.The result: a 40% reduction in scan time, a 20% increase in daily throughput, and PSMA waiting times down from over a month to approximately one week, all without adding a scanner or restructuring the clinical pathway.‍

Leapfrogging AI adoption in nuclear medicine

- By Maarten Larmuseau, CEO Nuclivision - Walk into RSNA, radiology's largest global conference, and you'll see the future of medical imaging taking shape right before your eyes. In December 2025, the technical exhibit floor was filled to the brim with companies from Microsoft, Siemens, and GE Healthcare down to five-person startups, all converging on the same two letters: “AI”. Finding a booth without "AI" in its marketing materials was nearly impossible, except for the occasional pure hardware vendor proudly staking their reputation on decades of craftsmanship. This AI omnipresence isn't just hype. Over 150 FDA-approved standalone medical imaging AI applications now exist, according to the Health AI Register [1]. Yet the distribution reveals a strong divide: 70 applications for CT, 50 for MRI, seven for PET, and just one for SPECT. While AI has saturated radiology, nuclear medicine remains largely unserved.

Clinical case study CHU de Liège

Read how one of Belgian's leading PET/CT centers implemented NUCLARITY to improve their operational efficiency and patient experience

EJNMMI publication of clinical validation study of NUCLARITY

Exciting news! Our clinical validation study for NUCLARITY has just been published in EJNMMI, a major milestone for our team and partners!

Nuclarity Clinical Study

Following our latest whitepaper from 2024, we have now included 6 readers in our extended clinical study conducted as part of Nuclarity's clinical evaluation. The analyis holds promising results for Nuclarity in terms of image quality and lesion detectability accuracy.